Guardion Health Sciences Inc Stock Price, News & Analysis

Guardion Health Sciences (NASDAQ:GHSI) has successfully completed a public offering of 37 million shares at $0.30, raising approximately $11.1 million before fees. The offering included Class A and Class B warrants, each with a $0.37 exercise price. Roth Capital Partners led the offering, with proceeds aimed at working capital and general corporate purposes. The offering was conducted under an SEC shelf registration effective since September 2020.

Guardion Health Sciences (NASDAQ:GHSI) has priced a public offering of 37,000,000 shares of common stock and warrants for gross proceeds of approximately $11.1 million. Each share and warrant are priced at $0.30, with Class A and Class B warrants exercisable at $0.37 per share. The offering is expected to close around February 23, 2022, subject to customary conditions. Funds will be used for working capital and general corporate purposes. Roth Capital Partners and Maxim Group are acting as agents for this offering.

Guardion Health Sciences (NASDAQ:GHSI) announced plans for a public offering of common stock and warrants to purchase common stock, exclusively by the Company. The offering remains subject to market conditions, without a definitive timeline for completion. Roth Capital Partners acts as the sole agent for this endeavor. Guardion aims to use the net proceeds for working capital and general corporate purposes. The Company has filed a shelf registration with the SEC, ensuring compliance with regulations.

Guardion Health Sciences, Inc. (GHSI) announced the launch of its first new Viactiv product since acquiring the brand in June 2021. The Omega BOOST gel bites provide 1,200 mg of Omega-3, a significant increase compared to leading gummies. Designed for better absorption and taste, these gel bites contain no sugar and no fishy aftertaste. Pre-orders begin on February 15, 2022. CEO Bret Scholtes highlighted the product's appeal to consumers seeking dietary supplements, particularly those already using calcium supplements.

Guardion Health Sciences, Inc. (Nasdaq: GHSI) has launched a new Shopify store for its Viactiv line of products, enhancing customer access and experience. The online store features the full Viactiv product range, including the new Calcium+Immune supplement, alongside educational content. This initiative aligns with the company's strategy to boost revenue through new sales channels. CEO Bret Scholtes emphasizes the store as a pivotal part of their growth plan for 2022.

Guardion Health Sciences (Nasdaq: GHSI) is set to present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference from January 10-13, 2022. CEO Bret Scholtes will lead the presentation, available on-demand starting January 10 at 7:00 a.m. ET. Guardion specializes in clinically supported nutrition, medical foods, and supplements aimed at aiding healthcare professionals and consumers in achieving health goals. The company emphasizes its strong scientific advisory board and ongoing developments in the clinical nutrition field.

Guardion Health Sciences (Nasdaq: GHSI) announced plans to wind down its VectorVision operations, focusing instead on its core clinical nutrition business. This decision aims to achieve a cost reduction of over $300,000 annually by reallocating resources to growth-oriented brands like Viactiv. The restructuring is expected to complete by March 31, 2022, allowing Guardion to explore licensing and distribution agreements related to its intellectual property, which may serve as an additional revenue stream.

Guardion Health Sciences, Inc. (Nasdaq: GHSI) has outlined significant developments in a recent Letter to Shareholders. The company has undergone a transformation in 2021, notably through the acquisition of the Viactiv brand, enhancing its product mix and revenue potential. Executive appointments, including Craig Sheehan as Chief Commercial Officer, aim to optimize operations and expand market share. Guardion focuses on bolstering brand awareness, efficient management, and product development to support growth. The company anticipates increased revenues and operational efficiencies from these strategic initiatives.

Guardion Health Sciences (Nasdaq: GHSI) appointed Michaela Griggs to its Board of Directors, enhancing its governance with her extensive healthcare marketing experience. Griggs, CEO of Southern California Reproductive Center, previously held executive roles at Allergan and Bayer Healthcare. The Board's vetting process emphasized her potential value in driving growth strategies and Environmental, Social, and Governance initiatives. Griggs expressed optimism about Guardion's growth trajectory, particularly following the acquisition of the Viactiv brand, which she believes will create significant marketing opportunities.